(Updates to include Lilly's comment in the fifth paragraph.)
Eli Lilly (LLY) closed up 3% Friday after media reports said US health officials are proposing a pilot program allowing Medicaid and some Medicare drug plans to cover costly weight loss medications.
The initiative would cover GLP-1 medicines for obesity, a category that includes Lilly's Zepbound, the reports said.
The pilot program for Medicaid may begin in April, with Medicare following in January 2027, the Washington Post reported, citing documents from the Centers for Medicare and Medicaid Services.
The proposal remains under review, the report said.
"Gaps in insurance coverage disrupt effective care and limit access to safe, evidence-based obesity management medications," a Lilly spokesperson said. "We are committed to working with payers and policymakers to expand coverage and improve care."
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。